Fig 1.
Enrollment and participation in NYC e-cigarette, or vaping, associated lung injury (EVALI) interviews, waves 1–3.
Table 1.
Demographic characteristics and hospitalization status among New York City residents who received a diagnosis of e-cigarette, or vaping, associated lung injury (EVALI) in 2019.
Table 2.
Vaping, e-cigarette, and substance use among New York City e-cigarette, or vaping, associated lung injury (EVALI) prospective follow-up respondents.
Table 3.
Clinical characteristics and effects of e-cigarette, or vaping, associated lung injury (EVALI) diagnosis among respondents.
Fig 2.
New symptoms after receiving EVALI diagnosis among the respondents who participated in all three interviews.
*Mental health includes attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), anxiety, depression, or post-traumatic stress disorder (PTSD); respiratory includes sleep apnea, asthma, or chronic obstructive pulmonary disorder; constitutional includes fevers, tiredness, or decreased appetite; and gastrointestinal includes nausea, vomiting, diarrhea, bloating, or abdominal pain.